Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: A placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D)
Access status:
Open Access
Type
ArticleAuthor/s
Saw, RP-MArmstrong, B
Mason, RS
Morton, RL
Shannon, KF
Spillane, AJ
Stretch, JR
Thompson, JF
Abstract
Patients with primary cutaneous melanomas that are ulcerated and >2 mm in thickness, >4 mm in thickness and those with nodal micrometastases at diagnosis, have few options for adjuvant treatment. Recent studies have suggested a role for vitamin D to delay melanoma recurrence and improve overall prognosis.Patients with primary cutaneous melanomas that are ulcerated and >2 mm in thickness, >4 mm in thickness and those with nodal micrometastases at diagnosis, have few options for adjuvant treatment. Recent studies have suggested a role for vitamin D to delay melanoma recurrence and improve overall prognosis.
See less
See less
Date
2014Publisher
BMC CancerLicence
Creative Commons Attribution 4.0Faculty/School
Faculty of Medicine and Health, NHMRC Clinical Trials CentreShare